AstraZeneca Pharma India Limited has informed the Exchange about Copy of Newspaper Publication
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India reported strong Q4 FY25 results with total income from operations rising about 27% year-on-year to Rs 496.6 crore (from Rs 391.9 crore in Q4 FY24). Net profit after tax for the quarter jumped roughly 48% to Rs 58.3 crore, and Q4 EPS rose to Rs 23.30 from Rs 15.79. For the full year FY25, revenue grew about 32% to Rs 1,756.9 crore, but annual net profit fell to Rs 115.7 crore from Rs 161.5 crore, with full-year EPS declining to Rs 46.30 from Rs 64.60. The profit dip is mainly because the company booked Rs 63.6 crore of expenses during the year related to the planned exit from its Bangalore manufacturing site, which is expected to cease operations in FY26. The company also changed its rounding convention from lakhs to millions of rupees starting Q1 FY25.
Short-term investors may focus on the solid Q4 rebound in revenue and profit, but the full-year earnings decline and ongoing Bangalore plant shutdown costs suggest margin pressure in the near term. The eventual sale or closure of the manufacturing site could unlock one-time value but adds uncertainty to FY26 numbers.